Welcome to our dedicated page for Dyadic Intl Del news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic Intl Del stock.
Dyadic International, Inc. (Nasdaq: DYAI), doing business as Dyadic Applied BioSolutions, regularly issues news on its activities as a global biotechnology company producing precision-engineered, animal-free proteins and enzymes. This news page aggregates press releases and market updates that describe how Dyadic is advancing its microbial C1 and Dapibus™ expression platforms across life sciences, food and nutrition, and bio-industrial markets.
Readers can find announcements about commercial agreements and partnerships, such as collaborations with Proliant Health and Biologicals, Inzymes ApS, Fermbox Bio, BRIG BIO, and Opes Diagnostics. These items often cover milestones in recombinant serum albumin, transferrin, growth factors, non-animal dairy proteins, and industrial enzyme products like EN3ZYME™, as well as details on licensing structures, milestone payments, and revenue-sharing arrangements.
Dyadic’s news flow also includes financial results and corporate developments, including quarterly earnings releases, equity offerings, and updates on its strategic shift from a research-driven organization to a commercially focused biotechnology company. These releases highlight progress in expanding product pipelines, scaling manufacturing, and strengthening liquidity to support commercial growth.
Another recurring theme in DYAI news is technology and platform validation. Articles describe grant-funded programs with organizations such as the Bill & Melinda Gates Foundation and CEPI, peer-reviewed publications demonstrating the capabilities of the C1 platform for vaccine antigens, and the CRISPR/Cas9 license agreement with ERS Genomics that broadens Dyadic’s genetic engineering toolkit.
Investors, analysts, and industry participants can use this page to follow Dyadic’s evolving portfolio of recombinant proteins, its regional expansion efforts, and its responses to Nasdaq listing matters disclosed in SEC filings. Bookmark this section to review the company’s historical and ongoing news as it reports commercial milestones, scientific progress, and capital markets activity.
Summary not available.
Dyadic International, Inc. (NASDAQ: DYAI) will report its financial results for the first quarter of 2023 on May 10, 2023, at 5:00 p.m. ET. This follows the company's focus on innovative microbial platforms aimed at increasing global protein bioproduction and improving access to biopharmaceutical products for human and animal health. Dyadic utilizes advanced technology based on the fungus Thermothelomyces heterothallica, enhancing the development and manufacturing of biologics. Their lead asset, DYAI-100, is a COVID-19 vaccine candidate, showcasing the company's commitment to addressing unmet clinical needs. A webcast of the conference call will be available post-event for investors and stakeholders.
Dyadic International, Inc. (NASDAQ: DYAI) announced a Notice of Allowance from the U.S. Patent and Trademark Office for its patent application titled "PRODUCTION OF FLU VACCINE IN MYCELIOPHTHORA THERMOPHILA." This patent is expected to provide protection through 2038 and covers the development and manufacture of seasonal and pandemic influenza vaccines using Dyadic’s C1 protein production platform. The human influenza vaccine market is valued at approximately $8 billion, projected to exceed $12 billion by 2028. CEO Mark Emalfarb highlighted the urgent need for efficient vaccine manufacturing platforms, especially in light of recent health crises. The patent strengthens Dyadic's intellectual property, bolstering its capacity to produce antigens and therapeutic proteins across diverse applications including oncology and diabetes.
Dyadic International (NASDAQ: DYAI) has expanded its licensing agreement with Rubic One Health to enhance the development and distribution of vaccines and biologics for human and animal health in Africa. This agreement builds on a previous collaboration focused on COVID-19 vaccines and now encompasses a wider range of therapeutic proteins beyond COVID-19.
As part of the deal, Dyadic will gain marketing rights and receive milestone and royalty payments from Rubic. The partnership aims to leverage Dyadic’s C1-cell protein expression platform, which is noted for its efficiency in production and reduced costs, to address the unmet healthcare needs in underserved regions.
CEO Mark Emalfarb highlighted the advantages of their C1 technology while Rubic's CEO Dr. Julian Naidoo emphasized the importance of this collaboration for Africa’s healthcare capabilities.
Dyadic International (NASDAQ: DYAI), a biotechnology company, announced its CEO, Mark Emalfarb, will present at the World Vaccine Congress in Washington, D.C. from April 4-6, 2023. Emalfarb's presentation, scheduled for April 5, will focus on transforming manufacturing and bridging technology gaps in vaccine production.
Additionally, he will provide an update on the Phase 1 Clinical Trial for the DYAI-100 COVID-19 vaccine. Key trial milestones include completing dosing in February 2023, with no serious adverse events reported and a full study report expected in the second half of 2023.
Dyadic International (NASDAQ: DYAI) has received regulatory approval for its Phase 1 trial of the DYAI-100 COVID-19 booster vaccine. The trial has successfully completed dosing for both low and high groups with no serious adverse events reported. The company reported a 21.9% year-over-year revenue increase for 2022, reaching approximately $2.93 million. Dyadic maintains cash and investments of $12.7 million, sufficient to fund operations into 2024. Significant collaborations with Janssen, Hengrui, and Phibro have been established, alongside the initiation of the Dapibus™ platform for microbial protein production. A conference call discussing financial results is scheduled for today at 5 PM ET.
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its financial results for the year ended 2022 and host a corporate update on March 29, 2023, at 5:00 p.m. ET. The company, focused on innovative microbial platforms for protein production and biopharmaceuticals, has developed C1 and Dapibus™ technologies. These platforms aim to lower production costs and enhance the performance of vaccines and biologics. Dyadic's initiatives include advancing its COVID-19 vaccine candidate, DYAI-100, and expanding its pipeline of biologic products. Investors can tune into the live conference call via the provided webcast link.
Dyadic International has completed dosing for all participants in its Phase 1 clinical trial of the DYAI-100 COVID-19 booster vaccine candidate. No serious adverse events have been reported, indicating a favorable safety profile thus far. This trial aims to assess both the safety and antibody response from the vaccine, produced using Dyadic's innovative C1-cell protein production platform. Results are anticipated in Q2 2023, with a comprehensive study report expected in the second half of the year. The study's success could enhance interest and adoption of Dyadic's technology across various sectors, including academic and governmental organizations.
Dyadic International, a biotechnology company listed on NASDAQ under the symbol DYAI, announced participation in key investor and industry events in March 2023. Notable engagements include the 16th European Conference on Fungal Genetics and the 35th Annual Roth Conference. The company’s innovative microbial platforms aim to meet the rising demand for affordable biopharmaceuticals.
Dyadic International, a biotechnology company, announced that CEO Mark Emalfarb will participate in two investor conferences: the BIO CEO & Investor Conference on February 6, 2023, in New York, and the 35th Annual Roth Conference from March 12-14, 2023, in California. Emalfarb is available for one-on-one meetings during these events. Dyadic focuses on innovative microbial platforms for protein bioproduction and biopharmaceuticals, including its lead asset, the DYAI-100 COVID-19 vaccine candidate. The company aims to enhance access to affordable health solutions globally.